Cancer Center Amsterdam
-
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
de Jonge, A. V., Bult, J. A. A., Karssing, D. F. E., Nijland, M., Chamuleau, M. E. D. & Brink, M., 1 Dec 2024, In: Blood Cancer Journal. 14, 1, 2.Research output: Contribution to journal › Article › Academic › peer-review
-
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS
de Jonge, A. V., Duetz, C., Bruins, W. S. C., Korst, C. L. B. M., Rentenaar, R., Cosovic, M., Eken, M., Twickler, I., Nijland, M., van der Poel, M. W. M., de Heer, K., Klerk, C. P. W., Strobbe, L., Oosterveld, M., Boersma, R., Koene, H. R., Roemer, M. G. M., van Werkhoven, E., Chamuleau, M. E. D. & Mutis, T., 12 Mar 2024, In: Blood. 8, 5, p. 1094-1104 11 p.Research output: Contribution to journal › Article › Academic › peer-review
-
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
de Jonge, A. V., van Werkhoven, E., Dinmohamed, A. G., Nijland, M., Zwinderman, A. H., Bossuyt, P. M., Veldhuis, M. S., Rutten, E. G. G. M., Mous, R., Vermaat, J. S. P., Sandberg, Y., de Jongh, E., Bilgin, Y. M., Boersma, R., Koene, H., Kersten, M. J., de Jong, D. & Chamuleau, M. E. D., 1 Dec 2023, In: Blood Cancer Journal. 13, 1, 85.Research output: Contribution to journal › Article › Academic › peer-review
- All publications